Indian drugmaker Aurobindo Pharma reported a lower first-quarter profit on Monday, as expenses grew faster than revenue - stung by weak prices in the key U.S. market.

Aurobindo Pharma on Monday reported a 10 per cent decline in its consolidated net profit to Rs 824 crore for the June quarter ...

Aurobindo Pharma's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA), margins and net profit was also ...

Aurobindo Pharma reports a 10.2% YoY drop in Q1 FY26 PAT, citing API sales and US market revenue decline. The company's ...

Aurobindo Pharma reports a 10% decline in consolidated net profit to Rs 824 crore for the June quarter, due to dwindling ...

Aurobindo Pharma Ltd. announced on Monday an interim dividend of Rs 4 per equity share with a face value of Re 1 for the ...

Aurobindo Pharma Ltd. reported a 10.3 per cent year-on-year (YoY) decline in consolidated net profit to Rs 824.2 crore in Q1 ...

Aurobindo Pharma reported a 10.2% YoY decline in Q1 net profit to ₹824.2 crore, missing CNBC-TV18 estimates. Revenue rose 4%, ...

Marico, Aurobindo Pharma, Kansai Nerolac, DLF, Escorts Kubota are among the top names that will announce their earnings for ...

Hyderabad: In a major strategic move, Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Aurobindo ...

Aurobindo Pharma USA acquires Lannett Company LLC for $250 million, expanding U.S. manufacturing capabilities and product ...

Aurobindo Pharma to acquire US-based Lannett for $250M, gaining a strategic local manufacturing base to offset tariffs and ...